Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(12/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(12/week)
News
United States
(1029/week)
Manufacturing
(493/week)
Technology
(1033/week)
Energy
(378/week)
Other Manufacturing
(323/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Indivior Group
Sep 26, 2018
Indivior Provides Update on Key Business Drivers and Expectations
Jul 31, 2018
Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld
Jul 27, 2018
FDA Approves PERSERIS(TM) (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Jun 28, 2018
Indivior's Temporary Restraining Order is Extended
May 31, 2018
Indivior Receives Subpoena from California Department of Insurance
May 25, 2018
Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence
May 14, 2018
Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case
Apr 20, 2018
Indivior Announces New Drug Submission to Health Canada for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder
Apr 05, 2018
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers
Mar 29, 2018
Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program
Feb 08, 2018
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers
Jan 03, 2018
Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABA(B) PAMs for Addiction Disorder Treatments
Dec 12, 2017
Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot
Nov 30, 2017
FDA Approves SUBLOCADE(TM) (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder
Oct 31, 2017
FDA Advisory Committees Recommend Approval of Indivior's RBP-6000 for the Treatment of Opioid Use Disorder
‹‹
Page 2
Latest News
May 29, 2024
Mitsubishi Electric Launches Serendie™ Digital Platform for Value Co-creation
May 29, 2024
AstroTurf Corporation Joins the Green Sports Alliance in a Major Move Toward Sustainability in Sports
May 29, 2024
Compass Minerals Announces Participation in Upcoming Investor Events
May 29, 2024
Water Recycling in Southern California Gets Major Funding Boost From Federal Government
May 29, 2024
Hitachi and Google Cloud Announce Strategic Partnership to Accelerate Innovation and Productivity with...
May 29, 2024
Faraday Future Announces Fiscal Fourth Quarter and Full Year 2023 Financial Results
May 29, 2024
Labrador Island Link Welcomes New Investor
May 29, 2024
Wolfer Finance Launches a Token Sale on Akemona for a Greener Bitcoin
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events